skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the management of restless legs syndrome: existing and emerging treatment options

Review

(1709) Views  (755) Full article downloads

Authors: Maurizio F Facheris, Andrew A Hicks, Peter P Pramstaller, et al

Published Date September 2010 Volume 2010:2 Pages 199 - 212
DOI: http://dx.doi.org/10.2147/NSS.S6946

Maurizio F Facheris1,2, Andrew A Hicks1, Peter P Pramstaller1,2,3, Irene Pichler1
1Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy (Affiliated institute of the University of Lübeck, Lübeck, Germany); 2Department of Neurology, Central Hospital, Bolzano, Italy; 3Department of Neurology, University of Lübeck, Germany

Abstract: Restless legs syndrome (RLS) is a sensorimotor disorder, characterized by a ­circadian variation of symptoms involving an urge to move the limbs (usually the legs) as well as paresthesias. There is a primary (familial) and a secondary (acquired) form, which affects a wide variety of individuals, such as pregnant women, patients with end-stage renal disease, iron deficiency, rheumatic disease, and persons taking medications. The symptoms reflect a circadian ­fluctuation of dopamine in the substantia nigra. RLS patients have lower dopamine and iron levels in the substantia nigra and respond to both dopaminergic therapy and iron administration. Iron, as a cofactor of dopamine production and a regulator of the expression of dopamine type 2-receptor, has an important role in the RLS etiology. In the management of the disease, the first step is to investigate possible secondary causes and their treatment. Dopaminergic agents are considered as the first-line therapy for moderate to severe RLS. If dopaminergic drugs are contraindicated or not efficacious, or if symptoms are resistant and unremitting, gabapentin or other antiepileptic agents, benzodiazepines, or opioids can be used for RLS therapy. Undiagnosed, wrongly ­diagnosed, and untreated RLS is associated with a significant impairment of the quality of life.

Keywords: pathophysiology, quality of life







Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The pathophysiology of bronchiectasis
Clinical evaluation of zaleplon in the treatment of insomnia
Obstructive sleep apnea syndrome: natural history, diagnosis, and emerging treatment options
Pharmacotherapy for treatment-resistant schizophrenia
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio